• Publications
  • Influence
Arginine deprivation as a targeted therapy for cancer.
A pegylated form of ADI (ADI-PEG20) has been formulated and has shown in vitro and in vivo activity against melanoma and hepatocellular carcinoma and future direction in utilizing this agent is discussed.
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
Elimination of all detectable plasma arginine in patients with metastatic melanoma was well tolerated and may be effective in the treatment of this cancer.
Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence, and Glutamine Addiction
It was shown that c-Myc, not elevated ASS1 expression, is involved in upregulation of many of these enzymes because knockdown of c- myc reduced their expression, whereas overexpressed ASS1 by transfection reduced theirexpression.
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
Use of histamine as an adjunct to IL-2 is safe, well tolerated, and associated with a statistically significant prolongation of survival compared with IL-1 alone in metastatic melanoma patients with liver involvement.
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
It is shown that ADI-PEG20 activates Ras signaling and the effector extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K)/AKT/GSK-3β kinase cascades, resulting in phosphorylation and stabilization of c-Myc by attenuation of its ubiquitin-mediated protein degradation mechanism.
Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes
Results suggest that targeted cancer cell metabolism through modulation of HIF-1α and c-Myc expression may improve the efficacy of ADI-PEG20 in treating Arg auxotrophic tumors.
Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.
It is found that arginine deprivation inhibits mTOR signaling but leads to activation of MEK and ERK with no changes in BRAF, which most likely lead to autophagy, a possible mechanism to survive by recycling intracellularArginine.
The natural history of resectable metastatic melanoma (Stage IVA Melanoma)
Stage IVA melanoma appears to be distinctly different in prognosis from Stage IVB melanoma and should be classified separately, and patients with recurrent soft‐tissue disease may benefit significantly from treatment with BCG.
Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy.
It is hypothesized that MAR patients generate autoantibodies against a melanoma antigen that cross react with bipolar cells of the retina that may cause abnormalities of the rod and cone systems that are characteristic of MAR.
Pegylated arginine deiminase: a novel anticancer enzyme agent
  • L. Feun, N. Savaraj
  • Biology, Medicine
    Expert opinion on investigational drugs
  • 21 June 2006
Pegylated arginine deiminase (ADI-PEG20) is a novel anticancer enzyme that produces depletion of arginine, which is a nonessential amino acid in humans. Certain tumours, such as malignant melanoma